Legend Biotech Reports 2025 Results as Carvykti Scales in Early-Line Myeloma
Key Takeaways
- Legend Biotech (LEGN) has released its full-year 2025 financial results, showcasing significant revenue growth driven by the continued commercial expansion of its lead CAR-T therapy, Carvykti.
- The company highlighted major manufacturing milestones and a strategic pivot toward solid tumor indications following a year of intensive market penetration in earlier lines of multiple myeloma treatment.
Mentioned
Key Intelligence
Key Facts
- 1Legend Biotech reported its Q4 and Full Year 2025 results on March 10, 2026.
- 2Carvykti commercial revenue saw significant year-over-year growth following expansion into second-line therapy.
- 3The company successfully scaled manufacturing capacity at its Ghent, Belgium and Raritan, New Jersey facilities.
- 4R&D focus expanded in 2025 to include targeted therapies for neuroendocrine carcinoma (NEC).
- 5Cash runway is projected to extend into 2027 based on current milestone and revenue trajectories.
Analysis
The release of Legend Biotech’s fourth-quarter and full-year 2025 results on March 10, 2026, marks a definitive transition for the company from a clinical-stage biotech to a commercial powerhouse in the cell therapy space. Throughout 2025, the primary narrative surrounding Legend has been the aggressive scaling of Carvykti (ciltacabtagene autoleucel), its blockbuster CAR-T therapy partnered with Johnson & Johnson’s Janssen Biotech. Following the landmark approvals for second-line treatment earlier in the year, the 2025 fiscal data reflects a significant uptick in patient volume and market share, particularly in the U.S. and European markets.
A critical component of the 2025 performance was the stabilization of the company’s manufacturing infrastructure. Legend Biotech spent much of the fiscal year optimizing its global supply chain, including the ramp-up of its Ghent facility in Belgium and the continued utilization of its Raritan, New Jersey site. These efforts were designed to address the historical bottleneck of CAR-T delivery: manufacturing capacity. By the end of Q4 2025, the company reported a substantial increase in its annual slot capacity, which has directly translated into the revenue growth observed in the year-end figures. This operational maturity is a key differentiator as Legend competes with Bristol Myers Squibb’s Abecma in the increasingly crowded BCMA-targeted landscape.
The release of Legend Biotech’s fourth-quarter and full-year 2025 results on March 10, 2026, marks a definitive transition for the company from a clinical-stage biotech to a commercial powerhouse in the cell therapy space.
Beyond the commercial success of Carvykti, the 2025 highlights point toward a strategic diversification of Legend’s oncology portfolio. While multiple myeloma remains the core revenue driver, the company has accelerated its research and development efforts in solid tumors, specifically targeting neuroendocrine carcinoma (NEC). This move is significant as the NEC market is projected to see substantial growth through 2036, and Legend’s entry into this space with targeted therapies represents a high-stakes attempt to replicate its liquid tumor success in more challenging solid tumor environments. The 2025 report confirms that several early-phase trials in these new indications have met their initial safety and dose-escalation milestones.
What to Watch
Financially, Legend Biotech enters 2026 with a robust balance sheet, bolstered by milestone payments from Janssen and a disciplined approach to R&D spending. While the company continues to operate at a net loss due to the high costs of cell therapy manufacturing and global clinical trials, the trajectory toward profitability has become clearer. Analysts are particularly focused on the company’s cash runway, which is now expected to extend well into 2027, providing ample cushion for the planned expansion of its pipeline. The 2025 results also reflect the impact of the Novartis contract manufacturing agreement, which has provided additional flexibility in meeting global demand.
Looking ahead, the industry will be watching for Legend’s ability to maintain its growth rate as it moves further into the frontline setting for multiple myeloma. The competition is expected to intensify as next-generation cell therapies and bispecific antibodies enter the market. However, Legend’s first-mover advantage in the second-line setting and its established manufacturing footprint provide a formidable moat. The company’s focus for 2026 will likely shift toward securing regulatory approvals in emerging markets and advancing its solid tumor candidates into pivotal trials, cementing its status as a leader in the next generation of personalized medicine.
Timeline
Timeline
Label Expansion
Carvykti receives FDA approval for earlier lines of multiple myeloma treatment.
Manufacturing Milestone
Ghent facility reaches full operational capacity for commercial production.
Pipeline Update
Initial Phase 1 data released for solid tumor candidates in neuroendocrine carcinoma.
FY 2025 Earnings
Legend Biotech reports full-year financial results and 2026 strategic outlook.
Sources
Sources
Based on 2 source articles- manilatimes.netCore Molding Technologies Reports Full Year and Fourth Quarter 2025 ResultsMar 10, 2026
- manilatimes.netLegend Biotech Reports Fourth Quarter and Full Year 2025 Results and Recent HighlightsMar 10, 2026
How we covered this story
Every story in our healthcare coverage is assembled from multiple primary sources, cross-referenced for factual consistency, and scored along three independent dimensions: sentiment, operational impact, and source-cluster confidence. Single-source rumors and unverifiable claims do not pass our editorial gate. When a story shows "Verified by N sources" with N≥2, the development is independently corroborated; when N=1, we mark it explicitly so readers can weigh the signal accordingly.
Impact scoring uses a 1-10 scale weighted toward regulatory, financial, and operational consequence rather than coverage volume. A topic that runs in every outlet but moves no real decisions ranks lower than a niche regulatory filing that reshapes how operators in the healthcare space have to behave. Read our full methodology for the scoring rubric, our glossary for term definitions, and our trends index for the longitudinal view across the beat.
| Signal on this page | What it tells you |
|---|---|
| Verified by N sources | Independent corroboration count. N≥2 is our confidence floor; N=1 is marked explicitly. |
| Impact score (1-10) | Regulatory + financial + operational weight. 8+ signals an experienced-operator action item. |
| Sentiment | Five-tier classification trained on labeled healthcare-specific corpora. |
| Timeline | Where applicable, the related-events sequence that contextualizes today's development. |